TD Cowen maintains its Buy rating on Boston Scientific, signaling continued confidence in the medtech giant's growth prospects
Executive summary: TD Cowen maintained its Buy rating on Boston Scientific (BSX) stock. The affirmation signals continued analyst confidence despite recent mixed rating actions, potentially influencing investor perception and share price stability.
Who is involved: TD Cowen analyst team and Boston Scientific.
Likely next: Investors will watch for Boston Scientific's upcoming quarterly results and any further analyst rating updates or regulatory developments.
TD Cowen analysts affirmed their Buy recommendation on Boston Scientific (BSX), indicating that the firm remains optimistic about the company's medical device portfolio and future growth. The affirmation comes amid a backdrop of mixed analyst actions, including recent target cuts and overlapping overweight ratings from other firms. While the rating itself does not introduce new information, it reinforces a positive stance that may help stabilise investor sentiment ahead of upcoming earnings.
Timeline
- — TD Cowen Maintains a Buy Rating on Boston Scientific (BSX) (Yahoo Finance)
- — Piper Sandler Maintains Overweight Rating for Boston Scientific (BSX) (Yahoo Finance)
- — Truist Cuts Boston Scientific (BSX) ’s Target as Doctors Change How They Use Its Heart Device (Yahoo Finance)
- — Below Expected Outlook Pressured Boston Scientific (BSX) in Q1 (Yahoo Finance)
- — Truist Reiterates Buy Rating for Boston Scientific (BSX) (Yahoo Finance)
- — BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock (Yahoo Finance)
- — Is Boston Scientific (BSX) One of the Best Healthcare Stocks to Buy With the Highest Upside Potential? (Yahoo Finance)
Analysis — what this means
Likely next events
- Boston Scientific Q2 earnings release
- Any FDA approvals for new devices
Sectors affected
- Healthcare
- Medical Devices
Regulatory implications
- No direct regulatory impact from the rating; future FDA scrutiny on device safety could affect the stock.
Historical parallels
- Piper Sandler maintained an overweight rating for BSX on 2026-06-23
- Truist cut BSX's target price on 2026-06-22
- Below‑expected outlook pressured BSX in Q1 2026-06-17
- Truist reiterated a Buy rating for BSX on 2026-06-13
Contradictions
- Truist cut BSX target price while TD Cowen maintains a Buy rating
- Piper Sandler overweight rating contrasts with Truist’s concurrent target cut
Key entities
Sources
- TD Cowen Maintains a Buy Rating on Boston Scientific (BSX) — Yahoo Finance
- Piper Sandler Maintains Overweight Rating for Boston Scientific (BSX) — Yahoo Finance
- Truist Cuts Boston Scientific (BSX) ’s Target as Doctors Change How They Use Its Heart Device — Yahoo Finance
- Below Expected Outlook Pressured Boston Scientific (BSX) in Q1 — Yahoo Finance
- Truist Reiterates Buy Rating for Boston Scientific (BSX) — Yahoo Finance
- BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock — Yahoo Finance
- Is Boston Scientific (BSX) One of the Best Healthcare Stocks to Buy With the Highest Upside Potential? — Yahoo Finance